N6-甲基腺嘌呤修饰调节因子与肿瘤

doi:10.3760/cma.j.cn371439-20200615-00018

摘要/Abstract

摘要：

N⁶-甲基腺嘌呤(m⁶A)是真核生物信使RNA和长非编码RNA最主要的修饰,该修饰过程由m⁶A甲基转移酶及去甲基化酶动态调控,主要通过m⁶A识别蛋白发挥作用。m⁶A修饰可影响转录、剪接、定位、核转运、翻译及降解等RNA代谢的各个方面,其失调可导致RNA功能紊乱,基因表达异常。m⁶A修饰调节因子在多种肿瘤中表达失衡,与肿瘤的形成、增殖、分化、侵袭和转移相关。

关键词: 肿瘤, RNA,信使, 甲基化

Abstract:

N⁶-methyladenine (m⁶A) is the most abundant internal RNA modification found in a variety of eukaryotic messenger RNAs and long non-coding RNAs, which is dynamically regulated by m⁶A methyltransferases and demethylases, and mainly works after recognized by m⁶A binding proteins. m⁶A is involved in almost every step of the RNA life cycle, including RNA transcription, splicing, localization, nuclear transport, translation, and degradation. Disorder of m⁶A modification can lead to RNA dysfunction and abnormal gene expression. m⁶A modification regulators express abnormally in various cancers, and play an important role in cancer formation, proliferation, differentiation, invasion and metastasis.

Key words: Neoplasms, RNA, messenger, Methylation

曾娟, 杨向红. N⁶-甲基腺嘌呤修饰调节因子与肿瘤[J]. 国际肿瘤学杂志, 2021, 48(2): 96-100.

Zeng Juan, Yang Xianghong. N⁶-methyladenine methylation regulators and cancer[J]. Journal of International Oncology, 2021, 48(2): 96-100.

参考文献 42

[1]	Boccaletto P, Machnicka MA, Purta E, et al. MODOMICS: a database of RNA modification pathways[J]. Nucleic Acids Res, 2018,46(D1):D303-D307. DOI: 10.1093/nar/gkx1030. pmid: 29106616
[2]	Lin S, Choe J, Du P, et al. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells[J]. Mol Cell, 2016,62(3):335-345. DOI: 10.1016/j.molcel.2016.03.021. doi: 10.1016/j.molcel.2016.03.021 pmid: 27117702
[3]	Liu J, Eckert MA, Harada BT, et al. m⁶A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer[J]. Nat Cell Biol, 2018,20(9):1074-1083. DOI: 10.1038/s41556-018-0174-4. pmid: 30154548
[4]	Ma JZ, Yang F, Zhou CC, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6-methyladenosine-dependent primary microRNA processing[J]. Hepatology, 2017,65(2):529-543. DOI: 10.1002/hep.28885. doi: 10.1002/hep.28885 pmid: 27774652
[5]	Wang Q, Chen C, Ding Q, et al. METTL3-mediated m⁶A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance[J]. Gut, 2020,69(7):1193-1205. DOI: 10.1136/gutjnl-2019-319639. doi: 10.1136/gutjnl-2019-319639 pmid: 31582403
[6]	Li Y, Xiao J, Bai J, et al. Molecular characterization and clinical relevance of m⁶A regulators across 33 cancer types[J]. Mol Cancer, 2019,18(1):137. DOI: 10.1186/s12943-019-1066-3. pmid: 31521193
[7]	Zheng W, Dong X, Zhao Y, et al. Multiple functions and mechanisms underlying the role of METTL3 in human cancers[J]. Front Oncol, 2019,9:1403. DOI: 10.3389/fonc.2019.01403. doi: 10.3389/fonc.2019.01403 pmid: 31921660
[8]	Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2[J]. Hepatology, 2018,67(6):2254-2270. DOI: 10.1002/hep.29683. doi: 10.1002/hep.29683 pmid: 29171881
[9]	Zhang J, Bai R, Li M, et al. Excessive miR-25-3p maturation via N(6)-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression[J]. Nat Commun, 2019,10(1):1858. DOI: 10.1038/s41467-019-09712-x. pmid: 31015415
[10]	Zhu W, Si Y, Xu J, et al. Methyltransferase like 3 promotes colo-rectal cancer proliferation by stabilizing CCNE1 mRNA in an m⁶A-dependent manner[J]. J Cell Mol Med, 2020,24(6):3521-3533. DOI: 10.1111/jcmm.15042. doi: 10.1111/jcmm.15042 pmid: 32039568
[11]	Peng W, Li J, Chen R, et al. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway[J]. J Exp Clin Cancer Res, 2019,38(1):393. DOI: 10.1186/s13046-019-1408-4. doi: 10.1186/s13046-019-1408-4 pmid: 31492150
[12]	Deng R, Cheng Y, Ye S, et al. m⁶A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways[J]. Onco Targets Ther, 2019,12:4391-4402. DOI: 10.2147/ott.S201052. doi: 10.2147/OTT.S201052 pmid: 31239708
[13]	Li X, Tang J, Huang W, et al. The m⁶A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma[J]. Oncotarget, 2017,8(56):96103-96116. DOI: 10.18632/oncotarget.21726. doi: 10.18632/oncotarget.21726 pmid: 29221190
[14]	Cui Q, Shi H, Ye P, et al. m⁶A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells[J]. Cell Rep, 2017,18(11):2622-2634. DOI: 10.1016/j.celrep.2017.02.059. doi: 10.1016/j.celrep.2017.02.059 pmid: 28297667
[15]	Weng H, Huang H, Wu H, et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m⁶A modification[J]. Cell Stem Cell, 2018,22(2):191-205, e9. DOI: 10.1016/j.stem.2017.11.016. pmid: 29290617
[16]	Sun C, Chang L, Liu C, et al. The study of METTL3 and METTL14 expressions in childhood ETV6/RUNX1-positive acute lymphoblastic leukemia[J]. Mol Genet Genomic Med, 2019,7(10):e00933. DOI: 10.1002/mgg3.933. pmid: 31429529
[17]	Wu L, Wu D, Ning J, et al. Changes of N6-methyladenosine modulators promote breast cancer progression[J]. BMC Cancer, 2019,19(1):326. DOI: 10.1186/s12885-019-5538-z. pmid: 30953473
[18]	Chen Y, Peng C, Chen J, et al. WTAP facilitates progression of hepatocellular carcinoma via m⁶A-HuR-dependent epigenetic silencing of ETS1[J]. Mol Cancer, 2019,18(1):127. DOI: 10.1186/s12943-019-1053-8. doi: 10.1186/s12943-019-1053-8 pmid: 31438961
[19]	Li H, Su Q, Li B, et al. High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration[J]. J Cell Mol Med, 2020,24(8):4452-4465. DOI: 10.1111/jcmm.15104. doi: 10.1111/jcmm.15104 pmid: 32176425
[20]	Lan T, Li H, Zhang D, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3[J]. Mol Cancer, 2019,18(1):186. DOI: 10.1186/s12943-019-1106-z. doi: 10.1186/s12943-019-1106-z pmid: 31856849
[21]	Cheng X, Li M, Rao X, et al. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m⁶A modification of ID2 mRNA[J]. Onco Targets Ther, 2019,12:3421-3428. DOI: 10.2147/ott.S180954. pmid: 31118692
[22]	Barros-Silva D, Lobo J, Guimarães-Teixeira C, et al. VIRMA-dependent N6-methyladenosine modifications regulate the expression of long non-coding RNAs CCAT1 and CCAT2 in prostate cancer[J]. Cancers (Basel), 2020,12(4):771. DOI: 10.3390/can-cers12040771. doi: 10.3390/cancers12040771
[23]	Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase[J]. Cancer Cell, 2017,31(1):127-141. DOI: 10.1016/j.ccell.2016.11.017. doi: 10.1016/j.ccell.2016.11.017 pmid: 28017614
[24]	Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3[J]. Mol Cancer, 2019,18(1):46. DOI: 10.1186/s12943-019-1004-4. doi: 10.1186/s12943-019-1004-4 pmid: 30922314
[25]	Rong ZX, Li Z, He JJ, et al. Downregulation of fat mass and obesity associated (FTO) promotes the progression of intrahepatic cholangiocarcinoma[J]. Front Oncol, 2019,9:369. DOI: 10.3389/fonc.2019.00369. doi: 10.3389/fonc.2019.00369 pmid: 31143705
[26]	Zhuang C, Zhuang C, Luo X, et al. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis[J]. J Cell Mol Med, 2019,23(3):2163-2173. DOI: 10.1111/jcmm.14128. doi: 10.1111/jcmm.14128 pmid: 30648791
[27]	Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast can-cer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA[J]. Proc Natl Acad Sci U S A, 2016,113(14):E2047-E2056. DOI: 10.1073/pnas.1602883113. doi: 10.1073/pnas.1602883113 pmid: 27001847
[28]	Guo J, Wu Y, Du J, et al. Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression[J]. Oncogenesis, 2018,7(6):49. DOI: 10.1038/s41389-018-0054-6. pmid: 29904125
[29]	Jin D, Guo J, Wu Y, et al. m⁶A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC[J]. Mol Cancer, 2020,19(1):40. DOI: 10.1186/s12943-020-01161-1. doi: 10.1186/s12943-020-01161-1 pmid: 32106857
[30]	He Y, Hu H, Wang Y, et al. ALKBH5 inhibits pancreatic cancer motility by decreasing long non-coding RNA KCNK15-AS1 methylation[J]. Cell Physiol Biochem, 2018,48(2):838-846. DOI: 10.1159/000491915. doi: 10.1159/000491915 pmid: 30032148
[31]	Guo X, Li K, Jiang W, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m⁶A-YTHDF2-dependent manner[J]. Mol Cancer, 2020,19(1):91. DOI: 10.1186/s12943-020-01158-w. doi: 10.1186/s12943-020-01158-w pmid: 32429928
[32]	Tang B, Yang Y, Kang M, et al. m⁶A demethylase ALKBH5 inhi-bits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling[J]. Mol Cancer, 2020,19(1):3. DOI: 10.1186/s12943-019-1128-6. doi: 10.1186/s12943-019-1128-6 pmid: 31906946
[33]	Paris J, Morgan M, Campos J, et al. Targeting the RNA m⁶A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia[J]. Cell Stem Cell, 2019,25(1):137-148, e136. DOI: 10.1016/j.stem.2019.03.021. doi: 10.1016/j.stem.2019.03.021 pmid: 31031138
[34]	Xie H, Li J, Ying Y, et al. METTL3/YTHDF2 m⁶A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer[J]. J Cell Mol Med, 2020,24(7):4092-4104. DOI: 10.1111/jcmm.15063. doi: 10.1111/jcmm.15063 pmid: 32126149
[35]	Yang S, Wei J, Cui YH, et al. m⁶A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade[J]. Nat Commun, 2019,10(1):2782. DOI: 10.1038/s41467-019-10669-0. doi: 10.1038/s41467-019-10669-0 pmid: 31239444
[36]	Chen J, Sun Y, Xu X, et al. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells[J]. Cell Cycle, 2017,16(23):2259-2271. DOI: 10.1080/15384101.2017.1380125. pmid: 29135329
[37]	Zhong L, Liao D, Zhang M, et al. YTHDF2 suppresses cell prolife-ration and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma[J]. Cancer Lett, 2019,442:252-261. DOI: 10.1016/j.canlet.2018.11.006. doi: 10.1016/j.canlet.2018.11.006 pmid: 30423408
[38]	Wang X, Zhao BS, Roundtree IA, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency[J]. Cell, 2015,161(6):1388-1399. DOI: 10.1016/j.cell.2015.05.014. doi: 10.1016/j.cell.2015.05.014 pmid: 26046440
[39]	Bai Y, Yang C, Wu R, et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma[J]. Front Oncol, 2019,9:332. DOI: 10.3389/fonc.2019.00332. doi: 10.3389/fonc.2019.00332 pmid: 31131257
[40]	Jin D, Guo J, Wu Y, et al. m⁶A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP acti-vity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis[J]. J Hematol Oncol, 2019,12(1):135. DOI: 10.1186/s13045-019-0830-6. doi: 10.1186/s13045-019-0830-6 pmid: 31818312
[41]	Jia R, Chai P, Wang S, et al. m⁶A modification suppresses ocular melanoma through modulating HINT2 mRNA translation[J]. Mol Cancer, 2019,18(1):161. DOI: 10.1186/s12943-019-1088-x. doi: 10.1186/s12943-019-1088-x pmid: 31722709
[42]	Klinge CM, Piell KM, Tooley CS, et al. HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells[J]. Sci Rep, 2019,9(1):9430. DOI: 10.1038/s41598-019-45636-8. doi: 10.1038/s41598-019-45636-8 pmid: 31263129

N⁶-甲基腺嘌呤修饰调节因子与肿瘤

N⁶-methyladenine methylation regulators and cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.